A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines | NCT01749410 | Trialant
CompletedObservationalUpdated Sep 10, 2015
A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
ClinicalTrials.gov ID
NCT01749410
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Observational
Enrollment
33Actual
Last Update Posted
Sep 10, 2015Estimated
Start Date
May 2013
Primary Completion Date
May 2014Actual
Completion Date
May 2014Actual
Brief Summary
This study will evaluate the effectiveness and benefit of treatment with onabotulinumtoxinA in Chronic Migraine patients who have received a minimum of 7 treatment cycles.
Chronic Migraine, Headaches
onabotulinumtoxinA
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
15 or more headache days over a 30 day period
A minimum of 7 treatment cycles with onabotulinumtoxinA
Exclusion Criteria:
Any treatment cycle dose of onabotulinumtoxinA greater than 200 units